Compare Canopy Growth Corp (CGC) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canopy Growth Corp vs UiPath Inc — how do they compare? Canopy Growth Corp trades at $1 (market cap $399.40M), while UiPath Inc trades at $15.67 (market cap $8.08B). The key difference: UiPath Inc is far larger — about 20.2× Canopy Growth Corp's market cap, and UiPath Inc is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.
| CGC | PATH | |
|---|---|---|
Market Cap | $399.40M | $8.08B |
Sector | Health | Technology |
52-Week High | $1.92 | $19.29 |
52-Week Low | $0.86 | $9.38 |
Enterprise Value | $356.90M | $6.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CGC trades at $0.9701, up 4.07% in 24 hours, with a neutral technical signal and mixed analyst ratings (9 buy, 11 hold, 7 sell). The company reported Q1 2027 revenue growth of 13% year-over-year but continues to post net losses, with a negative net income margin of -92.38% in 2026. Cash flow trends show improving operational efficiency, though negative operating cash flow persists. Recent news highlights progress on profitability measures and anticipation of U.S. cannabis rescheduling decisions.
The outlook remains cautious due to persistent unprofitability and regulatory uncertainties, but cost-cutting and revenue growth offer potential upside. Key risks include high debt, competitive pressures, and delayed federal cannabis reforms. Analysts are divided, reflecting the stock's high-risk, high-reward profile amid ongoing turnaround efforts.
UiPath (PATH) trades at $15.05, up 7.5% amid an AI stock rally, with technical indicators showing bullish momentum despite an overbought RSI. The company demonstrates strong revenue growth, improving from $892M in 2022 to $1.43B in 2025, with net income turning positive in 2026. Recent earnings show mixed results with Q1 2026 missing expectations, but Q3 and Q4 2025 beating estimates. Analyst sentiment remains cautious with a $13.33 consensus target below current price.
PATH offers exposure to enterprise automation growth with improving profitability, but faces execution risks and competitive pressures. The stock trades at premium valuations (P/E 25.08, P/S 4.86) while cash flow trends show improvement from negative $182M in 2025 to projected negative $67M in 2026. Key risks include AI competition and software spending volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
